Benralizumab study for severe asthma in China
Treatments studied
Part of Lungs & breathing clinical trials.
This study looks at people in China with severe eosinophilic asthma who are starting a new medicine called benralizumab. It will collect information about their symptoms and quality of life to understand who benefits most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You have been diagnosed with severe eosinophilic asthma (a type of asthma linked to high levels of certain white blood cells).
- Your doctor has decided to prescribe benralizumab (Fasenra) for your asthma.
- A recent blood test shows your eosinophil level is 150 or higher within the last 3 months, or 300 or higher within the last year.
- You are not currently in another clinical trial and have not had a prior allergic reaction to benralizumab.
- You have no history of cancer and have not used benralizumab before now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with severe eosinophilic asthma who are starting benralizumab. It looks at how well the treatment works in real life, outside of a controlled research setting.
This study tests if adding a new injectable medicine (benralizumab) to your current medium-dose inhaler works better than simply increasing your inhaler dose to control hard-to-treat asthma. It may help people with a specific type of asthma linked to high eosinophil levels.
This study is for people with severe eosinophilic asthma who are about to start a medicine called Benralizumab (Fasenra). It will observe how the medicine works in real life, and requires you to answer some questions about your asthma every week and month.
This trial studies whether a specific “signature” from asthma tests can predict who will respond to benralizumab (a severe asthma biologic). If you qualify, the researchers will compare your test results to how well benralizumab controls your asthma and prevents flare-ups.
This study is creating a registry to track the long-term safety and effectiveness of biologic treatments for severe asthma in Taiwan. If you are taking a biologic like omalizumab, mepolizumab, or benralizumab, joining this registry helps doctors learn how well these medicines work over time.
This trial lets people who completed an earlier benralizumab study and are benefiting from the medicine keep receiving it. The goal is to provide ongoing access while we continue to monitor safety and effectiveness.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.